Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Safety Measures Will Guests Expect as Travel Booms this Summer?

On this episode of A Move In The Light Direction, a podcast by Surfacide UV Technology, host Daniel Litwin talked with Wendy Walling, Director of Global Marketing at Intellego Technologies, and Jeff Veenhuis, President and CEO, Surfacide Manufacturing. The trio spoke about trends in summer travels as the U.S. meets new highs in travel demand…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

On this episode of A Move In The Light Direction, a podcast by Surfacide UV Technology, host Daniel Litwin talked with Wendy Walling, Director of Global Marketing at Intellego Technologies, and Jeff Veenhuis, President and CEO, Surfacide Manufacturing.

The trio spoke about trends in summer travels as the U.S. meets new highs in travel demand and how these will impact safety expectations for brick-and-mortar locations. Overall, travel demand has increased for the summer, which is good news for the travel industry.

As the European Union recommends the return of non-essential travel for U.S. passengers to boost their economy, the U.S. itself is seeing travel numbers similar to 2019, which was an excellent year for travel.

We recently crossed 2 million passengers crossing check-in thresholds in a single day, the TSA reported. Venues across the country are also seeing high traffic again, which also impacts the hospitality industry, but safety expectations have changed due to COVID.

“Whether it’s travel or hotels, consumers are really looking for safety protocols,” Walling said. “They want to see it in the policy and in the practice. They want to see evidence of it. The brands I think are going to do well and manage the influx of travel again are the ones prepared to handle that.”

However, not everything is so peachy in the travel industry, as the world-shaking effect of COVID-19 lingers on with new variants. These could potentially lead to more restrictions on travelers and even more expectations for health and well-being.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512